KR101968894B1 - Composition comprising Streptococcus pneumoniae strain and culture medium thereof - Google Patents

Abstract

A novel Streptococcus sp. Strain, and a culture solution thereof. According to one aspect of the present invention, there is provided a composition comprising a Streptococcus sp. Strain or a culture thereof, wherein the strain or a culture thereof has an excellent activity of enhancing the activity of the keratinocyte, A composition for external application for skin, a pharmaceutical composition, a health functional food, and the like.

Description

A composition comprising Streptococcus pneumoniae strain and culture thereof, which composition comprises Streptococcus pneumoniae strain and culture medium,

A novel Streptococcus sp. Strain, and a culture solution thereof.

The skin's ecosystem provides microorganisms with various forms of habitat and a wide range of microorganisms. It is known that the host, a human, has a symbiotic relationship with them and has a positive effect on the host. The skin forms a variety of habitats, such as intrusions and specialized crevices, and helps a wide range of microorganisms grow. Basically, the skin forms a physical film and helps to defend against potential hazards and toxins from the outside. The skin is the point of connection to the external environment and is also a collection of various microorganisms (fungi, bacteria, viruses and small larvae). To accommodate the choice of physical and chemical functions, microorganisms adapt to specialized crevices and establish habitats. In general, the skin is cold, acidic, and remains dry. Structurally, the epidermis forms a skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in maintaining moisture. The uppermost layer of the epidermis consists of the stratum corneum. The epidermis has a form called a 'brick and mortar structure'. The skin tissue undergoes a continuous self-healing process, and the squames that have undergone the differentiation process are repeatedly eliminated from the skin tissue.

Probiotics are microorganisms that give beneficial effects to the human body. Most probiotics known to date are known as lactobacilli. Although probiotics have been reported to have efficacious efficacy through various beneficial effects on the human body, there is little research on the interrelationship between the skin and the skin.

Skin barrier is composed of dead keratinocyte and intercellular lipids, protects skin from external stimuli, and protects skin from evaporation of water. It is a skin barrier that plays a key role in skin health. In other words, it prevents excessive release of water in the body and prevents harmful substances such as chemicals and microorganisms from entering our bodies. It plays an important role in intercellular lipid stability in keratinocyte envelope, which constitutes the surface of dead keratinocytes. The keratinocytes undergo differentiation to form a skin barrier through the keratinization process. Skin barrier function can be aged or destroyed by external factors, and damage to the skin barrier can cause skin moisture loss and wrinkles.

Accordingly, the present inventors have completed the present invention by isolating and identifying a novel Streptococcus sp. Strain from the skin of an adult and confirming the skin improving effect thereof.

Patent Registration No. 10-1698200

One aspect is to provide a strain of Streptococcus pneumoniae KCCM12005P.

Another aspect is to provide a cosmetic composition comprising a strain of Streptococcus pneumoniae KCCM12005P or a culture thereof.

Another aspect is to provide a composition for an external preparation for skin comprising Streptococcus pneumoniae strain KCCM12005P or a culture thereof.

Another aspect is to provide a pharmaceutical composition comprising a strain of Streptococcus pneumoniae KCCM 12005P or a culture thereof.

Another aspect is to provide a health functional food composition comprising Streptococcus pneumoniae strain KCCM12005P or a culture thereof.

One aspect provides a strain of Streptococcus pneumoniae KCCM 12005P.

In one embodiment of the present invention, the strain may comprise a 16s rRNA gene having the nucleotide sequence shown in SEQ ID NO: 1.

Another aspect provides a cosmetic composition comprising Streptococcus pneumoniae strain KCCM12005P or a culture thereof.

As used herein, the term " culture medium " refers to the culture medium obtained by culturing the strain, or the concentrate or lyophilizate of the culture supernatant obtained by removing the strain from the culture medium. &Quot; or " conditioned medium ".

In one embodiment of the present invention, the culture broth is prepared by cultivating Streptococcus pneumoniae KCCM 12005P strain in a Tryptic Soy medium or MRS medium treated with tryptone at a temperature of 20 to 42 캜 for 45 to 50 For a period of time.

In one embodiment of the invention, the culture supernatant of the strain can be obtained by a step of centrifuging or filtering the strain culture to remove the strain.

In one embodiment of the present invention, the concentrate can be obtained by filtering the culture broth itself or the culture broth using centrifugation or a filter, and then concentrating the supernatant obtained.

The culture medium and culture conditions for culturing Streptococcus pneumoniae strain are well known in the art and can be suitably selected or modified by those of ordinary skill in the art.

In one embodiment of the present invention, the culture solution obtained by culturing the strain or strain has a function of enhancing the activity of normal keratinocyte cells or keratinocytes aged by stimulation or promoting lipid production, and a barrier enhancing function .

In one embodiment, the cosmetic composition enhances skin barrier, prevents, improves or inhibits aging, and can prevent or improve inflammation. The skin barrier enhancement may be to increase expression of ABCA12 (ATP binding cassette subfamily A member 12) or to increase TGase-1 (Transglutaminase-1) expression. In addition, prevention, amelioration or inhibition of said aging may be to increase the activity of the cell or to promote lipid production. As used herein, the term " skin aging " refers to the type and intangible changes that appear on the skin with age, such as skin thinning, the number of dermal cells or blood vessels, DNA damage recovery, Refers to a reduction in wound healing, skin barrier function, epidermal water retention, sweat secretion, sebum secretion, vitamin D production, physical damage protection, chemical abilities, immune response, sensory function, and body temperature control. The Streptococcus pneumoniae KCCM12005P strain or culture thereof may be used for improving skin aging caused by an extrinsic factor or an endogenous factor. The extrinsic factor refers to various external factors such as ultraviolet (light), and the endogenous factor is also referred to as a chronological factor, which is mainly caused by the passage of time. Specifically, the skin aging specifically includes not only early symptoms of aging induced by external stimuli such as ultraviolet rays, pollution, smoke, chemicals, etc., but also natural aging phenomena caused by aging of skin cells And is a concept that includes both wrinkles, elasticity reduction, skin burning and drying phenomenon. Also, wrinkles include those in which irritation caused by changes in internal and external factors changes the constituents of the skin tissue to cause wrinkles.

Therefore, the composition can be effectively used for skin improvement, for example, skin moisturization, skin aging inhibition, skin barrier enhancement, and skin inflammation suppression by having the above effects.

The composition may be present in an amount of from 0.001% to 80%, such as from 0.01% to 60%, from 0.01% to 40%, from 0.01% to 30%, from 0.01% to 20% %, 0.01% to 10%, 0.01% to 5%, 0.05% to 60%, 0.05% to 40%, 0.05% to 30%, 0.05% to 20% From 0.05% to 10%, from 0.05% to 5%, from 0.1% to 60%, from 0.1% to 40%, from 0.1% to 30%, from 0.1% to 20% % To 10% by weight, or 0.1% to 5% by weight of the strain or a culture thereof.

In the present invention, the cosmetic composition may have cosmetic formulations of softening agent, nutritional lotion, massage cream, nutritional cream, essence, pack, gel, ampoule or skin sticking type.

The ingredients contained in the cosmetic composition of the present invention may contain, as an active ingredient, the ingredients conventionally used in cosmetic compositions in addition to the above-mentioned ingredients, for example, conventional additives such as stabilizers, solubilizers, vitamins, And a carrier.

Another aspect provides a composition for external application for skin comprising Streptococcus pneumoniae strain KCCM12005P or a culture thereof.

Streptococcus pneumoniae strain KCCM12005P or a culture thereof is as described above.

In the present invention, the external preparation for skin may be a cream, a gel, an ointment, a skin emulsifier, a skin suspension, a transdermal patch, a drug containing bandage, lotion, or a combination thereof. The external preparation for skin is usually used as a component used in external skin preparations such as cosmetics or medicines such as an aqueous component, an oily component, a powder component, an alcohol, a moisturizer, a thickener, an ultraviolet absorber, a whitening agent, an antiseptic, , Coloring agents, various skin nutrients, or a combination thereof, and may be suitably blended as necessary. The external preparation for skin may be a metal blocker such as sodium edetate, sodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate or gluconic acid, caffeine, tannin, bellapamil, licorice extract, glabridine, Vitamin C, ascorbic acid magnesium phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, fructose, fructose and other herbal medicines, various herbal medicines, tocopherol acetate, glycyrrhizic acid, Sugars such as trehalose and the like can also be appropriately compounded.

Another aspect provides a pharmaceutical composition comprising a strain of Streptococcus pneumoniae KCCM 12005P or a culture thereof.

Streptococcus pneumoniae strain KCCM12005P or a culture thereof is as described above.

The pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, the lubricant may be magnesium stearate, talc, or combinations thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low substituted hydroxy cellulose, or a combination thereof. The disintegrant may be carboxymethylcellulose calcium, starch glycolate sodium, calcium monohydrogen phosphate anhydrate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or combinations thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated into an oral or parenteral dosage form. Oral administration formulations may be granules, powders, solutions, tablets, capsules, dry syrups, or combinations thereof. The parenteral dosage form may be an injectable.

Another aspect provides a health functional food composition comprising Streptococcus pneumoniae strain KCCM 12005P or a culture thereof.

Streptococcus pneumoniae strain KCCM12005P or a culture thereof is as described above.

The health functional food composition may be used together with Streptococcus pneumoniae strain KCCM 12005P or culture thereof alone or another food or food ingredient, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the composition of the present specification may be added in an amount of not more than 15 parts by weight based on the raw material in the production of food or beverage. There is no particular limitation on the kind of the health functional food. Among the kinds of health functional foods, the beverage composition may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The health food composition may further comprise at least one selected from the group consisting of nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, The carbonating agent used, or a combination thereof. The health functional food composition may also contain natural fruit juice, fruit juice beverage, flesh for the manufacture of vegetable drinks, or combinations thereof.

Further, another aspect provides a method of enhancing skin barrier function, or preventing or ameliorating an aging of an individual comprising treating an individual with an effective amount of the above composition. The composition is the same as described above.

The subject may be a mammal, such as a person, a cow, a horse, a pig, a dog, a sheep, a goat, or a cat.

According to one aspect of the present invention, there is provided a composition comprising a Streptococcus sp. Strain or a culture thereof, wherein the strain or a culture thereof has an excellent activity of enhancing the activity of the keratinocyte, A composition for external application for skin, a pharmaceutical composition, a health functional food, and the like.

FIG. 1 is a graph showing the results of treatment of cells subjected to aging by stimulation with Poly I: C in a HaCaT cell line, culturing the culture of the CX-2 strain or co-culturing the cells with the CX-2 strain, (Scale bar: 400 mu m).
FIG. 2 is a graph showing the results of treatment of cells subjected to aging by stimulation with Poly I: C in a HaCaT cell line, culturing the culture of the CX-2 strain or co-culturing the cell with the CX-2 strain and culturing the cell with an ATP binding cassette subfamily A member 12) relative expression of the gene (## p <0.01, ** p <0.01).
FIG. 3 is a graph showing the relative expression of the TGase-1 gene and the expression of the TGase-1 gene after treatment of the culture with the CX-2 strain or by co-culturing the cell with the CX-2 strain to the cells aged by stimulation after treating the HaCaT cell line with Poly I: (P < 0.01, ** p < 0.01).
Fig. 4 shows the results of treatment of HaCaT cell line with UV-treated cells after stimulation to treat cells of CX-2 culture or co-culturing the cells with CX-2, (Scale bar: 400 mu m).

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these embodiments are intended to illustrate one or more embodiments, and the scope of the present invention is not limited to these embodiments.

Example  1. Isolation of strain

A healthy female skin was washed with sterile distilled water and the obtained sample was inoculated into R2A medium. After the inoculation, the cells were cultured in a 28 ° C incubator for 48 hours. 100 colonies were cultivated and cultured for 48 hours in a 28 ° C incubator. The cultured colonies were subjected to 16s rRNA gene sequencing. The primers used here were designed to amplify only in response to bacteria, and the nucleotide sequence information is shown in Table 1 below.

Forward primer 5'-AGAGTTTGATCMTGGCTCAG-3 ' Reverse primer 5'-TACGGYTACCTTGTTACGACTT-3 '

PCR amplification was performed at 30 cycles of 95 ° C for 1 minute, 55 ° C for 1 minute, and 75 ° C for 1 minute and 30 seconds. Finally, the PCR amplification was carried out at 72 ° C for 8 minutes and then stored at 4 ° C. After the PCR reaction, the DNA sequences of the isolated cultures were determined using ABI-3730XL (ABI, USA). The nucleotide sequence of the 16s rRNA region determined during the isolated cultured microorganism colony was compared with other strains registered with the BLAST program provided on the NCBI homepage. As a result, it was confirmed that the homology was 98%, and the isolated microorganism was designated as Streptococcus pneumoniae ( Streptococcus pneumoniae ).

The Streptococcus pneumoniae strain selected by the above method was named CX-2 and deposited under the Budapest Treaty on March 03, 2017 with the Korean Society for Microbiological Conservation (KCCM) to receive the deposit number KCCM12005P.

Example  2. Optimal culture condition analysis

In order to confirm the culture conditions of the strain isolated in Example 1, it was confirmed by culturing in Tryptic Soy medium and MRS medium treated with tryptone. Specifically, an API 50 CH kit (biomeriex, France) was used to determine the optimal culture conditions for the strain. The method of use was performed according to the manual provided by the manufacturer. Cultured cells were inoculated into each cube and cultured at 37 ° C for a maximum of 48 hours. The cells used in the test were cultured in a soybean agar medium treated with tryptone, and then harvested colonies were used. In case of color development, different color was developed for each test group, and accurate judgment was made by comparing with the test group of the test group. The contents of G + C contents, fatty acids, quinone, and polar lipids of isolated microorganisms were analyzed by KCCM (Korea Microorganisms Conservation Center). The optimum growth temperature was determined from 5 ℃ to 40 ℃ (5 ℃ interval). Optimum culture temperature was confirmed. Optimum salt concentration was 0 ~ 20% (1% interval) . The pH was determined by setting 4-8 intervals (0.5 intervals). Finally, optimal culture medium conditions were tested by slightly changing on the basis of commercially available medium and cultivation was carried out at 25 ° C.

As a result, it was confirmed that the optimum culture was possible when cultured in Tryptic Soy medium, MRS medium, at 37 ° C, in the range of 20 ° C to 42 ° C for 48 hours.

Example  3. The substance of the strain Usability  analysis

In order to analyze the material availability of the strain isolated in Example 1, the following procedure was performed.

BioLOG GP2, API 50, and the test method was used with reference to the test methods provided by Omnilog and Biomeriuse. The culture temperature and culture medium were incubated using the temperature suitable for the strain, and 5 colonies colonies cultured for 48 hours were suspended in the reagents. Inoculation amount was 150μl. The suspension used the components of the kit provided by each manufacturer. When the strain is not inoculated, it is in a transparent liquid state. The inoculated plates and strips were confirmed by incubation at 37 ° C for 48 hours and the results were confirmed up to 72 hours. Wells converted to purple or red were considered positive when they were inoculated at the time of inoculation. The results of the experiment as described above are shown in Table 2 below.

Characteristic Usability Lactose - Glycogen + Inulin + Melibiose + Raffinose - Ribose + Starch + Trehalose - Hydrolysis of arginine + N-acetyl-β-glucosaminidase (N-acetyl-β-glucosaminidase) - Alkaline phosphatase - α-D-Galactosidase (α-D-galactosidase) + β-D-galactosidase (β-D-galactosidase) + Glycyl-tryptophan arylamidase (Glycyl-tryptophan arylamidase) +

As shown in Table 2 above, the strain of the present invention can be used as a strain of the present invention in the presence of glycogen, inulin, melibiose, ribose, starch, arginine,? -D-galactosidase,? -D-galactosidase and glycyl- And it was confirmed that the use of multi - agent was possible.

Example  4. Lipid-secretory efficacy and cell activity analysis of keratinocytes by strain

In order to determine the effect of the strain isolated in Example 1 on lipid secretion efficiency and cell activity of keratinocytes, the following procedure was performed.

The HaCaT cell line, which is a human keratinocyte cell line, was treated with polyinosinic (Poly I: C), a synthetic ribonucleic acid that promotes the production of interferon, and cultured for 24 hours to stimulate the HaCaT cell line. After culturing, cells aged by stimulation were treated with a culture of CX-2 or co-cultured with CX-2.

The lipid and cellular activities secreted from the cells treated as described above were confirmed by oil red O staining. Specifically, 0.7 g of oil red O (hereinafter referred to as "ORO") and 200 ml of 99% isopropyl alcohol were mixed to prepare an oil red Ostark solution. The working solution was prepared by mixing the oil red O stark solution: distilled water at a ratio of 6: 4 and then filtered. The HaCaT cell line treated as described above was inoculated at 1 × 10 ⁴ cells per well of a 4 well chamber slide and cultured for 1-2 days. For induction of differentiation into 70-80% grown cell lines, the drug medium was mixed with 2 x 10 ^-8 M testosterone and 1 x 10 ^-4 M linoleic acid for 24 hours. After the medium was exchanged, 1 μM dexamethasone and the sample were treated together and oil red O staining was performed after 24 hours. The result of observing the stained cell line through an optical microscope is shown in Fig. Poly-I: C treated group, CX-2 treated group, CX-2 treated group, and CX-2 treated co-cultured group were treated with poly IC for the HaCaT cell line, One group was labeled with CX-2 strain and co-cultured group.

As shown in FIG. 1, when the culture of the CX-2 strain was treated after stimulation of the cells, the cell activity of HaCaT cell line was increased and lipid production was significantly promoted. In addition, when HaCaT cell line and CX-2 strain were co-cultured, cell activity and lipid production capacity of HaCaT cell line were also increased.

Example  5. Analysis of barrier function normalization effect of keratinocytes by strain

In order to examine the effect of the strain isolated in Example 1 on the enhancement of barrier function of keratinocytes, the following procedure was performed.

The HaCaT cell line, which is a human keratinocyte cell line, was treated with polyinosinic (Poly I: C), a synthetic ribonucleic acid that promotes the production of interferon, and cultured for 24 hours to stimulate the HaCaT cell line. After incubation, cells aged by stimulation were treated with a culture of CX-2, or co-cultured with CX-2, and analyzed by real-time RT-PCR using ABCA12 (ATP binding cassette subfamily A member 12) gene and the TGase-1 gene. RNA was extracted from the HaCaT cell line treated as described above, and RNA was nano-dropped. 16 μl of RNA was quantitatively treated at 70 ° C for 5 minutes, and then placed in a PCR premix and lightly taxed. Then, the mixture was treated at 42 ° C for 55 minutes, treated at 70 ° C for 15 minutes, and stored at 4 ° C to synthesize cDNA. The synthesized cDNA was amplified by PCR. 2 μl of cDNA, 1 μl of a forward primer targeting each gene, 1 μl of a reverse primer, 6 μl of distilled water and 10 μl of a premix sample were mixed and incubated at 95 ° C for 3 minutes, Lt; 0 &gt; C for 30 seconds and 72 &lt; 0 &gt; C for 1 minute). The results for the ABCA12 gene and the TGase-1 gene are shown in FIG. 2 and FIG. 3, respectively. Poly-I: C treated group, CX-2 treated group, CX-2 treated group, and CX-2 treated co-cultured group were treated with poly IC for the HaCaT cell line, One group was labeled with CX-2 strain and co-cultured group.

As shown in FIG. 2, when the culture of the CX-2 strain was treated or the HaCaT cell line and the CX-2 strain were co-cultured after stimulation of the cells, the relative amount of ABCA12 decreased by stimulation was significantly increased Respectively.

As shown in FIG. 3, when the culture of the CX-2 strain was treated or the HaCaT cell line and the CX-2 strain were co-cultured after stimulation of the cells, the relative amount of TGase-1 decreased .

Therefore, since the relative amount of ABCA12 and TGase-1 was increased as a result of the culture of the CX-2 strain of the present invention or co-cultivation with the CX-2 strain, the barrier function was restored by the culture or co- It can be seen that there is an effect.

Example  6. Lipid-secretory activity and cell activity analysis of keratinocytes by strain

In order to determine the effect of the strain isolated in Example 1 on lipid secretion efficiency and cell activity of keratinocytes, the following procedure was performed.

HaCaT cell line, which is a human keratinocyte cell line, was treated with ultraviolet rays and cultured for 24 hours to stimulate HaCaT cell line. After culturing, cells aged by stimulation were treated with a culture of CX-2 or co-cultured with CX-2. The lipid and cellular activities secreted from the cells treated as described above were confirmed by oil red O staining, and the results are shown in FIG.

The group treated with CX-2 culture medium and the group co-cultured with CX-2 culture were treated with CX-2 culture medium, the group treated with ultraviolet light alone, the group treated with UV treatment, the group treated with CX- 2 strains and co-culture group.

As shown in FIG. 4, when the culture of CX-2 strain was treated after stimulation of cells, cell activity of HaCaT cell line was increased and lipid production was significantly promoted. In addition, when HaCaT cell line and CX-2 strain were co-cultured, cell activity and lipid production capacity of HaCaT cell line were also increased.

Korea Microorganism Conservation Center (overseas) KCCM12005P 20170403

<110> COSMAXBTI, INC. <120> Composition comprising Streptococcus pneumoniae strain and          culture medium thereof <130> 117762 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 1260 <212> RNA <213> Streptococcus pneumoniae <400> 1 gagttgcgaa cgggtgagta acgcgtaggt aacctgcctg gtagcggggg ataactattg 60 gaaacgatag ctaataccgc ataagagtag atgttgcatg acatttgctt aaaaggtgca 120 cttgcatcac taccagatgg acctgcgttg tattagctag ttggtggggt aacggctcac 180 caaggcgacg atacatagcc gacctgagag ggtgatcggc cacactggga ctgagacacg 240 gcccagactc ctacgggagg cagcagtagg gaatcttcgg caatggacgg aagtctgacc 300 gagcaacgcc gcgtgagtga agaaggtttt cggatcgtaa agctctgttg taagagaaga 360 acgagtgtga gagtggaaag ttcacactgt gacggtatct taccagaaag ggacggctaa 420 ctacgtgcca gcagccgcgg taatacgtag gtcccgagcg ttgtccggat ttattgggcg 480 taaagcgagc gcaggcggtt agataagtct gaagttaaag gctgtggctt aaccatagta 540 ggctttggaa actgtttaac ttgagtgcaa gaggggagag tggaattcca tgtgtagcgg 600 tgaaatgcgt agatatatgg aggaacaccg gtggcgaaag cggctctctg gcttgtaact 660 gacgctgagg ctcgaaagcg tggggagcaa acaggattag ataccctggt agtccacgct 720 gt; taagcactcc gcctggggag tacgaccgca aggttgaaac tcaaaggaat tgacgggggc 840 ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac gcgaagaacc ttaccaggtc 900 ttgacatccc tctgaccgct ctagagatag agttttcctt cgggacagag gtgacaggtg 960 gtgcatggtt gtcgtcagct cgtgtcgtga gatgttgggt taagtcccgc aacgagcgca 1020 acccctattg ttagttgcca tcatttagtt gggcactcta gcgagactgc cggtaataaa 1080 ccggaggaag gtggggatga cgtcaaatca tcatgcccct tatgacctgg gctacacacg 1140 tgctacaatg gctggtacaa cgagtcgcaa gccggtgacg gcaagctaat ctcttaaagc 1200 cagtctcagt tcggattgta ggctgcaact cgcctacatg aagtcggaat catccgatcc 1260                                                                         1260

Claims (15)

Streptococcus pneumoniae strain KCCM12005P. [Claim 2] The method according to claim 1, wherein the strain comprises the nucleotide sequence shown in SEQ ID NO: 1. Streptococcus pneumoniae strain KCCM12005P or a culture thereof. [Claim 4] The method according to claim 3, wherein the culture liquid is a culture liquid obtained by culturing Streptococcus pneumoniae KCCM 12005P strain, or a concentrate or lyophilized culture supernatant obtained by removing the strain from the culture medium. Composition. [Claim 4] The method according to claim 3, wherein the culture broth is selected from the group consisting of Streptococcus pneumoniae KCCM12005P strain in a Tryptic Soy medium treated with Tryptone, or MRS medium under temperature conditions of 20 to 42 DEG C for 45 to 50 hours And culturing the same. [Claim 4] The cosmetic composition according to claim 3, wherein the cosmetic composition is for skin barrier enhancement, prevention or improvement of skin aging caused by ultraviolet rays, or prevention or improvement of inflammation. delete [Claim 4] The cosmetic composition according to claim 3, wherein the strain or the culture liquid thereof is contained in an amount of 0.01 to 10% by weight based on the total weight of the composition. 4. The cosmetic composition according to claim 3, wherein the strain or a culture solution thereof increases cell activity. 4. The cosmetic composition according to claim 3, wherein the strain or a culture thereof promotes lipid production. 4. The cosmetic composition according to claim 3, wherein the strain or a culture thereof increases expression of ABCA12 (ATP binding cassette subfamily A member 12). 4. The cosmetic composition according to claim 3, wherein the strain or a culture thereof increases TGase-1 (Transglutaminase-1) expression. Streptococcus pneumoniae KCCM12005P strain or a culture thereof for improving the skin condition. The skin condition improving composition is used for skin barrier enhancement, for preventing or improving skin aging caused by ultraviolet rays, or for preventing inflammation Or improving the composition. A pharmaceutical composition comprising Streptococcus pneumoniae KCCM12005P strain or a culture thereof, which is for skin barrier strengthening, prevention or improvement of skin aging by ultraviolet rays, or prevention or amelioration of inflammation. Streptococcus pneumoniae strain KCCM12005P or a culture thereof.

Images